Skip to main content

GLP-3 Retatrutide

Next-Generation
Weight Loss Peptide.

Weight loss. Metabolic health. Liver function. Cardiovascular.

Target 3 of your body's receptors:

  1. 1GLP-1 Regulates appetite and insulin
  2. 2GIP Supports glucose handling
  3. 3Glucagon Signals the body to use stored energy

Once weekly subcutaneous injection in third-stage clinical trials

What the
Science Shows.

Weight loss. Metabolic health. Liver function. Cardiovascular.

28.7%
AVE. BODY WEIGHT LOSS
86%
LIVER FAT REDUCTION
41%
TRIGLYCERIDE REDUCTION

RESEARCH USE ONLY*

  • No insurance required.
  • No prescription needed.
  • Batch tested by an independent U.S. laboratory.

Currently in late-stage (Phase 3) clinical trials.
FDA Review anticipated 2027

GLP-3 Retatrutide vial with science card: 28.7% body weight loss, 86% liver fat reduction, 41% triglyceride reduction.

RESEARCH USE ONLY*

What the Science Shows.

AVE. BODY WEIGHT LOSS
28.7%
TRIGLYCERIDE REDUCTION
41%
LIVER FAT REDUCTION
86%
  • No insurance required.
  • No prescription needed.
  • Batch tested by an independent U.S. laboratory.
Next-Generation

Weight Loss Peptide.

Weight loss. Metabolic health. Liver function. Cardiovascular.

Target 3 of your body's receptors:

  1. GLP-1 Regulates appetite and insulin
  2. GIP Supports glucose handling
  3. Glucagon Signals the body to use stored energy

Once weekly subcutaneous injection in third-stage clinical trials

Currently in late-stage (Phase 3) clinical trials. FDA Review anticipated 2027

Choose where you are

  1. Starter

    Begin slow regardless of weight, age, sex, or prior use of semaglutide or tirzepatide.

    $110(10mg covers 7 weeks)
    Begin Protocol

  2. Build-Up

    Use Build-Up when you are increasing from the starting dose toward your steady dose.

    $210 Per Vial(20mg covers 1 month)
    Continue with Build Up

  3. Maintenance

    Use Maintenance when you have reached your steady weekly dose and plan to stay there.

    $110 Per Vial10mg
    Send my Maintenance Kit

Not sure where you are in your protocol?

What you should know.

How can you sell a peptide that’s still in clinical trials?

Peptides are simple molecules: chains of amino acids. Retatrutide has been in human trials since 2019, is currently in Phase 3, and FDA approval is anticipated in 2027. Catalyst sells the research-use-only version of the compound: a legal category distinct from the branded prescription drug Eli Lilly is bringing to market. No dosing guidance, no medical claims.

How is quality verified?

Catalyst batch-tests peptides at independent U.S.-based laboratories to the highest industry standards, including mass spectrometry confirming identity, HPLC measuring purity (>99% target), and sterility and endotoxin assays. An independent laboratory report (Certificate of Analysis) ships with every order. Learn how to read a COA.

What concentrations are available?

Catalyst offers GLP-3 peptides in two concentrations: 10mg and 20mg per vial.

How should peptides be stored?

Unreconstituted vials hold in a cool, dry place out of direct sunlight. After reconstitution, refrigerate at 2 to 8°C.

See more answers

Safety information

GLP-3 Retatrutide

This is not medical advice. The information below is drawn from published findings of Retatrutide's Phase 3 clinical trials. Always consult a qualified clinician before starting or changing any peptide protocol.

Common side effects

Most people experience nausea, fatigue, or GI upset, especially during the first few weeks of titration. These usually subside as the body adjusts. If symptoms are severe or persistent, hold the current dose for an extra week before escalating.

Talk to a clinician first about

  • A history of pancreatitis
  • Personal or family history of medullary thyroid carcinoma or MEN-2
  • Severe kidney or liver disease
  • Current pregnancy or breastfeeding

Stop and seek immediate care for

  • Severe abdominal pain that does not go away
  • Signs of an allergic reaction (rash, swelling, difficulty breathing)
  • Persistent vomiting or signs of dehydration
  • Yellowing of skin or eyes

Find your kit · Step 1 of 2

Have you taken Retatrutide before?

GLP-3 Retatrutide — Catalyst · Catalyst